An application that seeks to connect students to engage in collaborative learning.
Visikol Inc. is a company based in New Brunswick, New Jersey, specializing in advanced drug discovery services and bio-imaging technology. It develops and provides a range of products, including Visikol, an optical sectioning tool for plant tissues, and Visikol HISTO, a series of tissue clearing kits and reagents designed to enhance 3D imaging in tissue processing workflows. Visikol's technologies enable researchers to visualize specimens effectively, allowing for the identification of adulterants and assessment of sample quality. The company also offers comprehensive drug discovery services, including the development of 2D and 3D in vitro models, assays, and digital pathology solutions. By transforming tissues into high-resolution images and quantitative datasets, Visikol supports clients in making informed decisions during the drug discovery process. Additionally, the firm manufactures 3D immuno-labeling kits, facilitating rapid imaging of whole tissues and 3D cell culture models, thereby moving beyond traditional 2D sectioning methods.
NovoPedics, Inc. develops implantable meniscus replacement and regeneration medical device. The company is based in the United States.
Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, that specializes in developing therapeutics for various medical conditions, including blood cancers, autoimmune diseases, and HIV. Established in 2009, the company is focused on leveraging its lead product, Leukotoxin, a bacterial toxin that targets white blood cells, to create effective treatments. Leukotoxin is primarily aimed at addressing hematologic malignancies, but research suggests its potential in treating infectious diseases such as HIV/AIDS and tuberculosis, as well as a range of autoimmune disorders including rheumatoid arthritis, multiple sclerosis, and psoriasis. Actinobac Biomed's strategy encompasses three key areas: prioritizing the development of Leukotoxin as a targeted therapy for blood cancers, exploring its use for other significant diseases, and maintaining a robust pipeline of novel therapeutic agents through collaboration with Magellan BioScience.
MentiNova, Inc. is a pharmaceutical company based in Piscataway, New Jersey, that specializes in developing oral medications for the treatment of Parkinson's disease. Established in 2012, the company focuses on creating innovative drug therapies aimed at alleviating the symptoms associated with this neurodegenerative disorder. By providing effective treatment options, MentiNova aims to enhance the quality of life for patients suffering from Parkinson's disease and other related mental health conditions.
GeneAssess, Inc. is a New Jersey-based biotechnology company that is working to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging. The FRY gene appears to be found in the breast cancer model but also shows potential for other cancers. In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.
Affineti Biologics, a New Jersey-based company developing plaque-reducing dental hygiene products.
Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, that specializes in developing therapeutics for various medical conditions, including blood cancers, autoimmune diseases, and HIV. Established in 2009, the company is focused on leveraging its lead product, Leukotoxin, a bacterial toxin that targets white blood cells, to create effective treatments. Leukotoxin is primarily aimed at addressing hematologic malignancies, but research suggests its potential in treating infectious diseases such as HIV/AIDS and tuberculosis, as well as a range of autoimmune disorders including rheumatoid arthritis, multiple sclerosis, and psoriasis. Actinobac Biomed's strategy encompasses three key areas: prioritizing the development of Leukotoxin as a targeted therapy for blood cancers, exploring its use for other significant diseases, and maintaining a robust pipeline of novel therapeutic agents through collaboration with Magellan BioScience.
Snowdon, Inc. is a biopharmaceutical company based in Princeton, New Jersey, founded in 2005. The company focuses on the discovery and development of novel small-molecule therapeutics targeting pain, infectious diseases, and neurological disorders. Its lead preclinical compound, SND-121, aims to treat neuropathic pain and has demonstrated notable safety and efficacy in rodent models, employing a unique mechanism of action that distinguishes it from traditional analgesics. Additionally, Snowdon is developing SND-159 for tuberculosis and SND-226 for toxoplasmosis, while also engaging in early-stage discovery projects for innovative treatments for neurological disorders, including Fragile X Syndrome, a leading cause of autism and related behaviors. The company aims to address the significant unmet medical needs in these therapeutic areas, providing safe and effective treatment options.